Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelodysplastic syndromes | D009190 | — | D46 | 12 | 6 | 3 | — | 1 | 19 |
Preleukemia | D011289 | — | — | 12 | 6 | 3 | — | 1 | 19 |
Syndrome | D013577 | — | — | 11 | 5 | 2 | — | 1 | 17 |
Anemia | D000740 | EFO_0004272 | D64.9 | — | 1 | 2 | — | — | 3 |
Refractory anemia with excess of blasts | D000754 | — | D46.2 | — | — | 3 | — | — | 3 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 1 | 2 | — | — | 3 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | 1 | 2 | — | — | 3 |
Refractory anemia | D000753 | — | D46.4 | — | — | 2 | — | — | 2 |
Pancytopenia | D010198 | — | D61.81 | — | — | 1 | — | — | 1 |
Cytopenia | D000095542 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 5 | 4 | — | — | — | 6 |
Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 3 | — | — | — | 4 |
Myeloid leukemia | D007951 | — | C92 | 4 | 3 | — | — | — | 4 |
Trisomy | D014314 | — | Q92.2 | — | 2 | — | — | 1 | 3 |
Lymphoid leukemia | D007945 | — | C91 | 3 | 1 | — | — | — | 3 |
Carcinoma | D002277 | — | C80.0 | 2 | 2 | — | — | — | 3 |
Squamous cell carcinoma | D002294 | — | — | 2 | 2 | — | — | — | 3 |
Squamous cell neoplasms | D018307 | — | — | 2 | 2 | — | — | — | 3 |
Epidermolysis bullosa | D004820 | — | Q81 | 2 | 1 | — | — | — | 2 |
Epidermolysis bullosa dystrophica | D016108 | — | Q81.2 | 2 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 7 | — | — | — | — | 7 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | — | — | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
Drug common name | Rigosertib |
INN | rigosertib |
Description | Rigosertib is an N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties. It has a role as a microtubule-destabilising agent, an EC 2.7.11.21 (polo kinase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a conjugate acid of a rigosertib(1-). |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1 |
PDB | — |
CAS-ID | 592542-59-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1241855 |
ChEBI ID | — |
PubChem CID | 6918736 |
DrugBank | DB12146 |
UNII ID | 67DOW7F9GL (ChemIDplus, GSRS) |